Latest Administration News

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.

Axtec has secured a strategic partnership with MRI Software to integrate its full product suite into widely used Australian real estate software, opening a major distribution channel across agent networks nationwide.

Li-S Energy marked key commercial and regulatory milestones in Q2 2026, including ISO 9001:2015 certification for its lithium foil line, first commercial foil sale, and US air transport approvals for lithium-sulfur cells. The company also completed a major Battery Testing Centre expansion and began deep-ocean cell testing with MSubs.

Tasman Resources is gearing up for dual drilling campaigns at Lake Torrens and Parkinson Dam, supported by a recent $4 million placement and strategic asset sales.

Complii FinTech Solutions reported modest ARR growth and a key institutional contract in Q4 FY26, while advancing product development and managing cash flow pressures.

Victory Metals has delivered a major processing breakthrough with a 59-fold upgrade to a 7.1% Total Rare Earth Oxide concentrate from its North Stanmore project, backed by strategic partnerships and government funding.

Diablo Resources has acquired an 80% stake in the historic Horn Silver Project, complementing its nearby Star Range assets and advancing exploration with a maiden drill program approved.

Nelson Resources has kicked off underground drilling at its high-grade Orleans Mine while advancing rehabilitation at Great Western Mine and securing a strategic tungsten property adjacent to a major US project. Exploration spending reached $794k, supported by a $2.1 million cash buffer.

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.

Cycliq Group delivered steady quarterly receipts and returned to net operating cash inflow in Q4 FY2026, driven by a robust End of Financial Year sales campaign and strategic appointments aimed at expanding AI capabilities.

Multistack International ended the June quarter with a sharp drop in cash reserves following the disposal of its main undertaking, while ongoing operating cash outflows highlight a cautious outlook amid strategic transition.